Integration pattern of HIV-1 based lentiviral vector carrying recombinant coagulation factor VIII in Sk-Hep and 293T cells

Biotechnology Letters

Volumn 33, Issue 1, 2010, Pages 23-31

  de Sousa Russo Carbolante, Elisa Maria ^a,d   Picanço Castro, Virgínia ^a   Alves, Daiani Cristina Cilão ^a   Fernandes, Andrielle Castilho ^a   Almeida Porada, Graça ^b   Tonn, Torsten ^c   Covas, Dimas Tadeu ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF NEVADA   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Toxicologicas e Bromatologicas   (Brazil)

Author keywords

Coagulation factor VIII; Integration sites; Lentiviral vector

Indexed keywords

CELL CULTURE; COAGULATION; CYTOLOGY; DISEASES; GENES; INTEGRATION; TRANSCRIPTION;

CELL LINES; COAGULATION FACTOR; CPG ISLANDS; GENOMIC DNA; INTEGRATION PATTERNS; LENTIVIRAL VECTOR; SK-HEP-1; TRANSCRIPTION START SITE;

CELLS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 84893704349     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-010-0387-5     Document Type: Article

References (20)

1. Antequera F., Bird A (1999) CpG islands as genomic footprints of promoters that are associated with replication origins. Curr Biol 9:R661-R667
2. Beard B. C, Dickerson D, Beebe K, Gooch C, Fletcher J, Okbinoglu T., Miller DG, Jacobs MA, Kaul R, Kiem HP, Trobridge G. D (2007) Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 15:1356-1365
3. Cavazzana-Calvo M., Hacein-Bey S, de Saint Basile G, Gross F, Yvon E., Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672
4. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N., McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M., Fischer A (2003a) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256
5. Hacein-Bey-Abina S, Von Kalle C, SchmidtM, McCormack MP, Wulffraat N. et al (2003b) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419
6. Hacker C. V, Vink CA, Wardell TW, Lee S, Treasure P, Kingsman S. M, Mitrophanous KA, Miskin JE (2006) The integration profile of EIAV-based vectors. Mol Ther 14:536-545
7. Kim S., Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C., Klein EA, Lee C, Silverman RH, Chow SA (2008) Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol 82:9964-9977
8. Kustikova O., Fehse B, Modlich U, Yang M, Dullmann J, Kamino K., von Neuhoff N, Schlegelberger B, Li Z, BaumC (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174
9. Laufs S., Guenechea G, Gonzalez-Murillo A, Zsuzsanna Nagy K, Luz Lozano M., del Val C, Jonnakuty S, Hotz-Wagenblatt A, Jens Zeller W, Bueren JA, Fruehauf S (2006) Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med 8:1197-1207
10. Lavie L., Maldener E, Brouha B, Meese EU, Mayer J (2004) The human L1 promoter: variable transcription initiation sites and a major impact of upstream flanking sequence on promoter activity. Genome Res 14:2253-2260
11. Lewinski M. K, Yamashita M, Emerman M, Ciuffi A, Marshall H, Crawford G., Collins F, Shinn P, Leipzig J, Hannenhalli S, Berry C. C, Ecker JR, Bushman FD (2006) Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2:e60
12. Li Z., Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J., Forster M, Stocking C, Wahlers A, Frank O, Ostertag W., Kuhlcke K, Eckert HG, Fehse B, Baum C (2002) Murine leukemia induced by retroviral gene marking. Science 296:497
13. Mitchell R. S, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2:E234
14. Montini E., Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C., Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C., Doglioni C, von Kalle C, Naldini L (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687-696
15. Picanco V., Heinz S, Bott D, Behrmann M, Covas DT, Seifried E, Tonn T. (2007) Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter. Cytotherapy 9:785-794
16. Picanço-Castro V., Fontes AM, Russo-Carbolante EMS, Covas DT (2008) Lentiviral-mediated gene transfer-a patent review. Exp Opin Therap Patents 18(5):525-539
17. Rohdewohld H., Weiher H, Reik W, Jaenisch R, Breindl M (1987) Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J Virol 61:336-343
18. Tonn T., Herder C, Becker S, Seifried E, Grez M (2002) Generation and characterization of human hematopoietic cell lines expressing factor VIII. J Hematother Stem Cell Res 11:695-704
19. Venter J. C, Adams MD, Meyers E, Li PW, Mural RJ et al. (2001) The Sequence of the Human Genome. Science 1304-1351
20. Wu X., Li Y, Crise B, Burgess SM (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749-1751